FDA approves BioSphere's embolic catheter:
This article was originally published in Clinica
Executive Summary
BioSphere Medical has gained US FDA approval to sell its EmboCath hydrophilic infusion catheter, which can be used in conjunction with the firm's microsphere technology. The EmboCath catheter will offer physicians a more targeted and controlled method for delivery of embolic material compared with standard angiographic catheters, said the Rockland, Massachusetts firm. The company also claims that EmboCath is a cost-effective alternative to currently available high-end micro-catheters, used commonly in embolotherapy procedures. BioSphere also plans to bring the product into Europe, pending CE-mark approval.